drugset / Trial / NCT00026520
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
Treatment
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of the tumor. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining interferon alfa with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa with thalidomide in treating patients who have stage IV melanoma.
Timeline
- Start
- 2001-11
- Primary completion
- —
- Completion
- 2006-04
Publications
- Results Hutchins LF, Moon J, Clark JI, Thompson JA, Lange MK, Flaherty LE, Sondak VK. Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer. 2007 Nov 15;110(10):2269-75. doi: 10.1002/cncr.23035.
- Results Hutchins L, Moon J, Clark J, et al.: Interferon alpha-2b and thalidomide in previously treated patients with disseminated malignant melanoma: SWOG 0026. [Abstract] J Clin Oncol 22 (Suppl 14): A-7527, 716s, 2004.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | 200 mg | Oral |
| Subject | Thalidomide | Other / unclassified | 400 mg | Oral |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 1e+06 iu | Subcutaneous |